ONO Pharmaceutical Expands Use of Medidata
ONO will be conducting a series of clinical trials in Japan to assess the safety and efficacy of using OPDIVO for a wide range of additional indications, including head and neck cancer.
Japan-based company sponsor, ONO Pharmaceutical, is expanding its use of Medidata’s Clinical Cloud to evaluate additional indications for OPDIVO, a cutting-edge immunotherapy drug in Japan. ONO will be conducting a series of clinical trials in Japan to assess the safety and efficacy of using OPDIVO for a wide range of additional indications, including head and neck cancer.
A Medidata customer since 2012, ONO utilizes Medidata Rave to support its Phase II and III clinical trials in oncology, cancer anorexia/cachexia and diabetes.
Read the full
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
